Aurigene Pharmaceutical Services to expand biologics CDMO capacity with a new biomanufacturing facility
Aurigene Pharma announces the construction of a state-of-the art development and manufacturing facility for therapeutic proteins, antibodies, and viral vectors.
As a first step of investment plan, Aurigene is investing $40m in an R&D and pilot scale facility at Genome Valley, a well-known Biotechnology Park in Hyderabad. This facility will meet the process development and clinical supply needs of global biotech companies. The facility is planned to be fully operational in first half of 2024.This complements Aurigene’ s strong foundation in biotherapeutics discovery, contributing to accelerating global R&D-driven (bio)pharma companies’ biologics journey to the market by offering end-to-end and high-quality services for antibodies, proteins, and viral vectors.
Hyderabad, India. May 22, 2023: Aurigene Pharmaceutical Services Limited (Aurigene), a contract research, development, and manufacturing services organization and a step-down subsidiary of Dr. Reddy's Laboratories announces the construction of a state-of-the art development and manufacturing facility for therapeutic proteins, antibodies, and viral vectors.
As a first step of investment plan, Aurigene is investing $40m in an R&D and pilot scale facility at Genome Valley, a well-known Biotechnology Park in Hyderabad. This facility will meet the process development and clinical supply needs of global biotech companies. The facility is based on a state-of-the-art design concept, allowing maximum flexibility for a multi-product, multi-platform offering across therapeutic proteins, antibodies, and viral vectors. The facility is planned to be fully operational in first half of 2024.This complements Aurigene’ s strong foundation in biotherapeutics discovery, contributing to accelerating global R&D-driven (bio)pharma companies’ biologics journey to the market by:
· Offering end-to-end and high-quality services for antibodies, proteins, and viral vectors
· Dedicated scientific team with impeccable track-record of commercializing several biosimilars globally
· Global regulatory experience
Seamless access to commercial manufacturing – ready to scale quickly.
The expansion provides global customers access to a dedicated team and modern labs, including a pilot facility. This offer is complemented by exclusive access to an established large-scale GMP manufacturing facility.
Related News
-
News New Aurigene biologics facility opens in Hyderabad, India
Aurigene Pharmaceutical Services Ltd. have opened a biologics facility in Hyderabad, India in a biocluster known as Genome Valley. -
News Ophthalmologic drug product Eylea faces biosimilar threats after FDA approvals
Regeneron Pharmaceutical’s blockbuster ophthalmology drug Eylea is facing biosimilar competition as the US FDA approves Biocon’s Yesafili and Samsung Bioepis/Biogen’s Opuviz. -
News CPHI Barcelona Speaker Interview – What the US FDA’s Quality Management Maturity Means for the Pharma Industry
At CPHI Barcelona (24–26 October, 2023), we spoke to Sireesha Yadlapalli, CEO of Pharmatech Associates, who gave a presentation on the implications of the US FDA’s Quality Management Maturity (QMM) Initiative, and spoke on the panel of the ... -
News Women in Pharma: Empowering yourself and other women in pharma
In our new monthly series, we interview women from across the pharmaceutical industry and supply chain to discuss the importance of gender diversity in healthcare, the workplace, and beyond.
-
News Novartis agrees for copies to be made of cancer drug to reach poorer countries
Novartis signs agreement with MPP to have generics of it's leukemia drug made so that it can be more easily distributed to the world's poorer countries. -
News Doctors Without Borders demands transparency from GSK on licensing agreements for preventative HIV treatment
GSK has signed licensed agreements with three companies to manufacture generic versions of its preventative HIV medicine for distribution in lower-income countries but calls for increased transparency is putting pressure on the drugmaker. -
News Sai Life Sciences opens new HPAPI manufacturing facility in Bidar, India
A new HPAPI development and manufacturing block is now open at Sai Life Sciences’ Bidar Manufacturing Campus, expanding the CRDMO’s capabilities in small molecule discovery and commercialisation. -
News CPHI Pharma Award Winners 2022: CEO of the Year – Aragen Life Sciences
In this series of interviews, we speak to the teams behind the winning concepts at CPHI Pharma Awards 2022, in each of the different categories, from digital innovation to CEO of the year.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance